IDH1 and acute myeloid leukemia: This approach gained substantial clinical significance, exemplified by the recent regulatory approval of ivosidenib (AG‐120), the first selective mutant IDH1 inhibitor, for the treatment of IDH1‐mutated acute myeloid leukemia.59